With box warnings

Without box warnings

Branded

Generic

3 results

brilinta
(Ticagrelor)
AstraZeneca Pharmaceuticals LP
Usage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction, as well as for those with high-risk coronary artery disease. It also decreases stroke risk in patients with acute ischemic stroke or transient ischemic attack.
eptifibatide
(Eptifibatide)
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Usage: Eptifibatide injection is indicated to reduce the risk of death or new myocardial infarction in patients with acute coronary syndrome (ACS) and to decrease the rate of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI), including those receiving intracoronary stenting.
ticagrelor
(ticagrelor)
Solco Healthcare U.S., LLC
Usage: Ticagrelor is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lowers the risk of stent thrombosis and is used to reduce stroke risk in acute ischemic stroke and high-risk transient ischemic attack patients.

Medications for Acute Coronary Syndrome

brilinta